Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Novartis Aimovig not...

    Novartis Aimovig not cost effective: UK price watchdog

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2019-01-11T09:00:15+05:30  |  Updated On 16 Aug 2021 12:07 PM IST

    Novartis, whose U.K. price for Aimovig is about 5,000 pounds ($6,374) annually but which was offering discounts, is counting on the medicine to be a foundation of its neuroscience business and a key part of boosting revenue as older medicines lose patent protection. Some analysts see 2022 sales nearing $1 billion, according to Refinitiv.


    ZURICH: Britain's drug price watchdog on Thursday rejected Novartis's migraine drug Aimovig for now, concluding in a draft decision that the medicine was not a cost-effective use of National Health Service resources.


    Novartis, with exclusive rights to the drug in Europe, while cooperating with Amgen in the United States, said it was "disappointed" in the National Institute for Health and Care Excellence's (NICE) conclusion.


    Read Also: Novartis signs deal with Gan & Lee as US government seeks to slash insulin cost


    It marks the second time within months the U.K. agency has rejected reimbursement for a key medicine from the Swiss drugmaker.


    Novartis, whose U.K. price for Aimovig is about 5,000 pounds ($6,374) annually but which was offering discounts, is counting on the medicine to be a foundation of its neuroscience business and a key part of boosting revenue as older medicines lose patent protection. Some analysts see 2022 sales nearing $1 billion, according to Refinitiv.


    While NICE said the medicine demonstrated clinical effectiveness, the agency concluded there was not enough evidence to suggest it is more effective than botulinum toxin type A, which is marketed by Allergan as Botox. NICE also raised questions about long-term effectiveness.


    "We will work with the company to ensure that they are given every opportunity to address the issues highlighted in these provisional recommendations," NICE said.


    Read Also: Novartis to buy France's CellforCure to boost cell, gene therapy


    Novartis, which pledged to work with NICE to address outstanding questions, said patients would lack new treatment options if the decision remains unchanged. "The UK already lags significantly behind other European countries in the ability for patients to access new medicines," Novartis said.


    In September, NICE also issued draft guidance concluding Novartis's cancer cell therapy Kymriah, offered with an undisclosed discount to its list price of 282,000 pounds, was too expensive to recommend to treat adults with lymphoma. Novartis is also seeking to reverse that decision.

    Amgencancer cell therapydrug AimovigKymriahMigrainemigraine drugNational Health ServiceNational Institute for Health and Care ExcellenceNHSNICENovartisprice watchdogSwiss drugmakerU KUnited StatesZURICH
    Source : Reuters

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok